deltatrials

Multiple myeloma Trials in Dordrecht, Netherlands

Conditions / Multiple myeloma / Dordrecht, Netherlands

Clinical trials for Multiple myeloma investigate a range of treatment strategies and patient populations.

18 total trials for this combination

Showing top 10 of 18 trials

Trials

NCT ID Title Status Phase
NCT05243797 Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation RECRUITING PHASE3
NCT03871829 Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab TERMINATED PHASE2
NCT02654990 Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma COMPLETED PHASE2
NCT02181413 A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant COMPLETED PHASE3
NCT03652064 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy ACTIVE_NOT_RECRUITING PHASE3
NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) RECRUITING
NCT02136134 Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma COMPLETED PHASE3
NCT04975997 Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) ACTIVE_NOT_RECRUITING PHASE3
NCT05827016 A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma RECRUITING PHASE3
NCT05623020 A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant RECRUITING

Related Pages